
Ian J Woolley

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8583159/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Emergence of FY*Anull in a Plasmodium vivax-endemic region of Papua New Guinea. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 13973-13977.	3.3	218
2	HIV infection and high density lipoprotein metabolism. Atherosclerosis, 2008, 199, 79-86.	0.4	127
3	Splenectomy Associated Changes in IgM Memory B Cells in an Adult Spleen Registry Cohort. PLoS ONE, 2011, 6, e23164.	1.1	92
4	HIV infection and high-density lipoprotein: the effect of the disease vs the effect of treatment. Metabolism: Clinical and Experimental, 2006, 55, 90-95.	1.5	88
5	Guidelines for the prevention of sepsis in asplenic and hyposplenic patients. Internal Medicine Journal, 2008, 38, 349-356.	0.5	74
6	Low CD4 Count Is Associated With an Increased Risk of Fragility Fracture in HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, 205-210.	0.9	70
7	<p>Post-splenectomy sepsis: preventative strategies, challenges, and solutions</p> . Infection and Drug Resistance, 2019, Volume 12, 2839-2851.	1.1	63
8	HIV is associated with an increased risk of age-related clonal hematopoiesis among older adults. Nature Medicine, 2021, 27, 1006-1011.	15.2	62
9	Duffy-null promoter heterozygosity reduces DARC expression and abrogates adhesion of theP. vivaxligand required for blood-stage infection. FEBS Letters, 2001, 495, 111-114.	1.3	60
10	HIV Replication Alters the Composition of Extrinsic Pathway Coagulation Factors and Increases Thrombin Generation. Journal of the American Heart Association, 2013, 2, e000264.	1.6	59
11	Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial. Aids, 2010, 24, 2657-2663.	1.0	49
12	Fragility Fractures in HIV-Infected Patients: Need for Better Understanding of Diagnosis and Management. Journal of the International Association of Providers of AIDS Care, 2004, 3, 86-91.	1.2	39
13	Splenectomy sequelae: an analysis of infectious outcomes among adults in Victoria. Medical Journal of Australia, 2012, 196, 582-586.	0.8	34
14	Incidence and seroprevalence of dengue virus infections in Australian travellers to Asia. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31, 1203-1210.	1.3	34
15	Shedding light on DARC: the role of the Duffy antigen/receptor for chemokines in inflammation, infection and malignancy. Inflammation Research, 2009, 58, 431-435.	1.6	33
16	Incidence and risk factors for acute respiratory illnesses and influenza virus infections in Australian travellers to Asia. Journal of Clinical Virology, 2013, 57, 54-58.	1.6	33
17	Changes in the prevalence of lipodystrophy, metabolic syndrome and cardiovascular disease risk in HIV-infected men. Sexual Health, 2015, 12, 240.	0.4	32
18	A randomised controlled trial of omega-3 fatty acid supplementation for the treatment of hypertriglyceridemia in HIV-infected males on highly active antiretroviral therapy. Sexual Health, 2006, 3, 287.	0.4	31

#	Article	IF	CITATIONS
19	Healthy, safe and effective international medical student electives: a systematic review and recommendations for program coordinators. Tropical Diseases, Travel Medicine and Vaccines, 2019, 5, 4.	0.9	30
20	Cost-effectiveness of a post-splenectomy registry for prevention of sepsis in the asplenic. Australian and New Zealand Journal of Public Health, 2006, 30, 558-561.	0.8	29
21	Trends in detectable viral load by calendar year in the Australian HIV observational database. Journal of the International AIDS Society, 2011, 14, 10-10.	1.2	28
22	Disseminated Mycobacterium avium-intracellulare Complex (MAC) Infection in the Era of Effective Antiretroviral Therapy. Drugs, 2004, 64, 679-692.	4.9	27
23	Postsplenectomy infection - strategies for prevention in general practice. Australian Family Physician, 2010, 39, 383-6.	0.5	27
24	SARS-COV-2 vaccine acceptance in patients with rheumatic diseases: a cross-sectional study. Human Vaccines and Immunotherapeutics, 2021, 17, 4048-4056.	1.4	25
25	Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction. Internal Medicine Journal, 2005, 35, 67-68.	0.5	24
26	Cancer, immunodeficiency and antiretroviral treatment: results from the Australian <scp>HIV O</scp> bservational <scp>D</scp> atabase (<scp>AHOD</scp>). HIV Medicine, 2013, 14, 77-84.	1.0	24
27	Antiretroviral Treatment Interruption and Loss to Follow-Up in Two HIV Cohorts in Australia and Asia: Implications for †Test and Treat' Prevention Strategy. AIDS Patient Care and STDs, 2013, 27, 681-691.	1.1	23
28	Determinants of Viremia Copy-Years in People With HIV/AIDS After Initiation of Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, 55-64.	0.9	23
29	International travel in the immunocompromised patient: a cross-sectional survey of travel advice in 254 consecutive patients. Internal Medicine Journal, 2015, 45, 618-623.	0.5	23
30	Lichenoid drug eruption to tenofovir in an HIV/hepatitis B virus co-infected patient. Aids, 2004, 18, 1857-1858.	1.0	22
31	Maraviroc, as a Switch Option, in HIV-1–infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study. Clinical Infectious Diseases, 2016, 63, 122-132.	2.9	21
32	The Impact of the COVID-19 Pandemic on People Living with HIV in Victoria, Australia. AIDS Research and Human Retroviruses, 2021, 37, 322-328.	0.5	21
33	Clinic Network Collaboration and Patient Tracing to Maximize Retention in HIV Care. PLoS ONE, 2015, 10, e0127726.	1.1	21
34	Life-long antimicrobial therapy: where is the evidence?. Journal of Antimicrobial Chemotherapy, 2018, 73, 2601-2612.	1.3	20
35	Trends in mortality among ARTâ€treated HIVâ€infected adults in the Asiaâ€Pacific region between 1999 and 2017: results from the TREAT Asia HIV Observational Database (TAHOD) and Australian HIV Observational Database (AHOD) of IeDEA Asiaâ€Pacific. Journal of the International AIDS Society, 2019, 22, e25219.	1.2	19
36	The inside story. Physicians' views on digital ano-rectal examination for anal cancer screening of HIV positive men who have sex with men. Journal of Medical Screening, 2013, 20, 188-191.	1.1	18

#	Article	IF	CITATIONS
37	Low Risk of Japanese Encephalitis in Shortâ€Term Australian Travelers to Asia. Journal of Travel Medicine, 2013, 20, 206-208.	1.4	17
38	Surveillance of life-long antibiotics: a review of antibiotic prescribing practices in an Australian Healthcare Network. Annals of Clinical Microbiology and Antimicrobials, 2017, 16, 3.	1.7	17
39	The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) singleâ€tablet regimen in the expanding spectrum of fixedâ€dose combination therapy for HIV. HIV Medicine, 2020, 21, 3-16.	1.0	17
40	Acute pancreatitis caused by tipranavir/ritonavir-induced hypertriglyceridaemia. Aids, 2007, 21, 532-533.	1.0	16
41	Predictors of chronic kidney disease and utility of risk prediction scores in HIV-positive individuals. Aids, 2018, 32, 1829-1835.	1.0	16
42	High Dose Cytosine Arabinoside is a Major Risk Factor for the Development of Hepatosplenic Candidiasis in Patients with Leukemia. Leukemia and Lymphoma, 1997, 27, 469-474.	0.6	14
43	Eosinophilic folliculitis. Aids, 2004, 18, 2350-2352.	1.0	14
44	Visiting friends and relatives may be a risk for non-adherence for HIV-positive travellers. International Journal of STD and AIDS, 2012, 23, 833-834.	0.5	14
45	High rates of potentially infectious exposures between immunocompromised patients and their companion animals: an unmet need for education. Internal Medicine Journal, 2017, 47, 333-335.	0.5	14
46	Expression of Duffy antigen receptor for chemokines during reticulocyte maturation: using a CD71 flow cytometric technique to identify reticulocytes. Immunohematology, 2005, 21, 15-20.	0.2	13
47	C-reactive protein as a predictor of cardiovascular risk in HIV-infected individuals. Sexual Health, 2014, 11, 580.	0.4	12
48	Platelet phenotype and function in the absence of splenic sequestration (Review). Platelets, 2021, 32, 47-52.	1.1	11
49	Case Report: Japanese Encephalitis Associated with Chorioretinitis after Short-Term Travel to Bali, Indonesia. American Journal of Tropical Medicine and Hygiene, 2020, 103, 1691-1693.	0.6	11
50	The Significance of HIV †Blips' in Resource-Limited Settings: Is It the Same? Analysis of the Treat Asia HIV Observational Database (TAHOD) and the Australian HIV Observational Database (AHOD). PLoS ONE, 2014, 9, e86122.	1.1	10
51	Temporal trends of time to antiretroviral treatment initiation, interruption and modification: examination of patients diagnosed with advanced HIV in Australia. Journal of the International AIDS Society, 2015, 18, 19463.	1.2	10
52	Treatment and disease outcomes of migrants from low- and middle-income countries in the Australian HIV Observational Database cohort. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2015, 27, 1410-1417.	0.6	10
53	Spleen registry may help reduce the incidence of overwhelming postsplenectomy infection in Victoria. Medical Journal of Australia, 2010, 192, 49-50.	0.8	9
54	Acanthamoeba Encephalitis: Isolation of Genotype T1 in Mycobacterial Liquid Culture Medium. Journal of Clinical Microbiology, 2015, 53, 735-739.	1.8	9

#	Article	IF	CITATIONS
55	<i>Mycobacterium haemophilum</i> bone and joint infection in HIV/AIDS: case report and literature review. International Journal of STD and AIDS, 2015, 26, 974-981.	0.5	9
56	Low rates of endocarditis in healthcare-associated Staphylococcus aureus bacteremia suggest that echocardiography might not always be required. European Journal of Clinical Microbiology and Infectious Diseases, 2016, 35, 49-55.	1.3	9
57	Burden of infective endocarditis in an Australian cohort of people who inject drugs. Internal Medicine Journal, 2020, 50, 1240-1246.	0.5	9
58	Diffuse alveolar damage following a single administration of a cyclophosphamide containing chemotherapy regimen. Australian and New Zealand Journal of Medicine, 1997, 27, 605-606.	0.5	8
59	Successful use of eltrombopag without splenectomy in refractory HIV-related immune reconstitution thrombocytopenia. Aids, 2012, 26, 1977-1979.	1.0	8
60	Cardiovascular disease and diabetes in <scp>HIV</scp> â€positive and HIVâ€negative gay and bisexual men over the age of 55 years in Australia: insights from the Australian Positive & Peers Longevity Evaluation Study. HIV Medicine, 2019, 20, 121-130.	1.0	8
61	Review of HIV testing recommendations in Australian specialty guidelines for HIV indicator conditions: a missed opportunity for recommending testing?. Internal Medicine Journal, 2020, 50, 293-298.	0.5	8
62	The significance of low-level viraemia in diverse settings: analysis of the Treat Asia HIV Observational Database (TAHOD) and the Australian HIV Observational Database (AHOD). HIV Medicine, 2014, 15, 406-416.	1.0	7
63	Increasing Prevalence and Risk of Chronic Kidney Disease in Human Immunodeficiency Virus–Infected Individuals: Changing Demographics Over a 6-Year Period. Journal of Infectious Diseases, 2018, 217, 1013-1015.	1.9	7
64	Chronic kidney disease in Australian Human Immunodeficiency Virusâ€infected patients: Analysis of the Australian HIV Observational Database. Nephrology, 2018, 23, 778-786.	0.7	7
65	Impact of a spleen registry on optimal post-splenectomy vaccination and care. Human Vaccines and Immunotherapeutics, 2018, 14, 2894-2899.	1.4	7
66	Coronavirus disease 2019 (COVIDâ€19): not one epidemic but four. Internal Medicine Journal, 2020, 50, 657-658.	0.5	7
67	The two-edged sword: vasculitis associated with HIV and hepatitis C coinfection. International Journal of STD and AIDS, 2014, 25, 77-88.	0.5	6
68	Recent Trends in Early Stage Response to Combination Antiretroviral Therapy in Australia. Antiviral Therapy, 2015, 20, 131-139.	0.6	6
69	An analysis of the thromboembolic outcomes of 2472 splenectomized individuals. Blood, 2015, 125, 1681-1682.	0.6	6
70	Intermittent negative blood cultures in Staphylococcus aureus bacteremia; A retrospective study of 1071 episodes. Open Forum Infectious Diseases, 2019, 6, ofz494.	0.4	6
71	Prevalence and distribution of functional splenic tissue after splenectomy. Internal Medicine Journal, 2020, 50, 556-564.	0.5	6
72	Sequential cutaneous drug reactions to protease inhibitors in the context of occupational post-exposure prophylaxis. Aids, 2003, 17, 1709.	1.0	5

#	Article	IF	CITATIONS
73	The Influence of Splenectomy on the Infectious Complications and Outcomes of people With HIV: Marked, Sustained Elevation in Risk of Severe Infection With Bacteria Including Streptococcus pneumoniae. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, e24-e26.	0.9	5
74	Understanding of the significance and health implications of asplenia in a cohort of patients with haemaglobinopathy: possible benefits of a spleen registry. Hematology, 2018, 23, 526-530.	0.7	5
75	Surveillance of life-long antibiotics—A cross-sectional cohort study assessing patient attitudes and understanding of long-term antibiotic consumption. Infection, Disease and Health, 2019, 24, 179-186.	0.5	5
76	Clinical and financial burden of spinal infections in people who inject drugs. Internal Medicine Journal, 2022, 52, 1741-1748.	0.5	5
77	Caught in the actâ \in \mid a case of fulminant amoebic colitis. JMM Case Reports, 2015, 2, .	1.3	5
78	Long-Term Outcomes in Patients on Life-Long Antibiotics: A Five-Year Cohort Study. Antibiotics, 2022, 11, 62.	1.5	5
79	Febrile illness in a returned traveller: could it be primary HIV?. Medical Journal of Australia, 2001, 175, 172-172.	0.8	4
80	Clostridium septicum Bacteremia Without Gas Gangrene as a Late Consequence of a Contaminated Wound. Surgical Infections, 2004, 5, 315-317.	0.7	4
81	Unrecognised vitamin D deficiency: low concentrations in African migrants with HIV in Australia. Sexual Health, 2008, 5, 375.	0.4	4
82	Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study. HIV Medicine, 2018, 19, 65-71.	1.0	4
83	Cambodian-born individuals diagnosed with HIV in Victoria: epidemiological findings and health service implications. Sexual Health, 2007, 4, 209.	0.4	3
84	Tenofovir Therapy for Hepatitis B May Be Commonly Prescribed Without HIV Testing. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, e53-e54.	0.9	3
85	Treatment durability and virological response in treatment-experienced HIV-positive patients on an integrase inhibitor-based regimen: an Australian cohort study. Sexual Health, 2016, 13, 335.	0.4	3
86	Isn't it time to talk about antiretroviral stewardship?. Journal of Chemotherapy, 2016, 28, 352-354.	0.7	3
87	Physician testing for HIV in patients treated with tenofovir disoproxil fumarate and lamivudine monotherapy for hepatitis B virus. Sexual Health, 2018, 15, 89.	0.4	3
88	Management of gonorrhoea in a hospital network: are we following best practice?. Sexual Health, 2019, 16, 523.	0.4	3
89	Southeast Asian ovalocytosis is associated with increased expression of Duffy antigen receptor for chemokines (DARC). Immunohematology, 2009, 25, 63-66.	0.2	3
90	Occupational exposures experienced by medical students during overseas electives. Healthcare Infection, 2006, 11, 123-133.	0.1	2

#	Article	IF	CITATIONS
91	Macrolide use and the risk of vascular disease in HIV-infected men in the Multicenter AIDS Cohort Study. Sexual Health, 2007, 4, 111.	0.4	2
92	Reducing Viral Load Measurements to Once a Year in Patients on Stable, Virologically Suppressive Cart Regimen: Findings from the Australian HIV Observational Database. Journal of AIDS & Clinical Research, 2014, 5, .	0.5	2
93	Latent infection in HIVâ€positive refugees and other immigrants in Australia. Medical Journal of Australia, 2015, 202, 238-240.	0.8	2
94	Initial modelling and updates on cost effectiveness from the first 10 years of a spleen registry. Australian and New Zealand Journal of Public Health, 2018, 42, 463-466.	0.8	2
95	Human immunodeficiency virusâ€infected young people in Australia: data from the Australian HIV Observational Database. Internal Medicine Journal, 2018, 48, 1447-1456.	0.5	2
96	Triple class experience after initiation of combination antiretroviral treatment in Australia: survival and projections. Sexual Health, 2011, 8, 295.	0.4	2
97	Re: Published article – patient knowledge of the risks of postâ€splenectomy sepsis <i>ANZ J. Surg.</i> 2008; 78: 867–70. ANZ Journal of Surgery, 2009, 79, 854-856.	0.3	1
98	Acute HIV infection presenting as erythema multiforme in a 45â€yearâ€old heterosexual man. Medical Journal of Australia, 2015, 203, 137-137.	0.8	1
99	HIV presenting as AIDS in previously undiagnosed tourists in a low-prevalence setting. Aids, 2019, 33, 1952-1954.	1.0	1
100	Routine testing for hyposplenism in a lupus clinic diagnoses; new cases and opportunities for intervention. Lupus, 2021, 30, 687-688.	0.8	1
101	Underutilised <scp>human immunodeficiency virus</scp> testing in the setting of invasive pneumococcal disease. Internal Medicine Journal, 2021, 51, 968-970.	0.5	1
102	Transmissible spongiform encephalopathy and new variantCreutzfeldt-Jakob disease. Clinical Microbiology Newsletter, 1998, 20, 165-168.	0.4	0
103	Piroplasmosis. Clinical Microbiology Newsletter, 1998, 20, 25-28.	0.4	Ο
104	Shooting At the DARC: Potential Issues with Species-Specific Antimalarials. Infectious Disorders - Drug Targets, 2012, 12, 357-359.	0.4	0
105	Acute Mediastinal Melioidosis: Diagnosis By Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration. , 2012, , .		Ο
106	Macrophage migration inhibitory factor. Aids, 2014, 28, 1693-1694.	1.0	0
107	A history of infection with varicella is strongly predictive of the presence of varicella-zoster virus antibodies in a heterogenous Australian HIV cohort. Aids, 2015, 29, 2062-2064.	1.0	Ο
108	Cryptococcal/CSF ventricular levels on MRI brain in a man with AIDS. Radiology of Infectious Diseases, 2017, 4, 170-171.	2.4	0

#	Article	IF	CITATIONS
109	Selected state of the art research in internal medicine, 2017. Internal Medicine Journal, 2018, 48, 619-623.	0.5	0
110	Infectious diseases physician attitudes to long-term antibiotic use. International Journal of Clinical Pharmacy, 2019, 41, 18-21.	1.0	0
111	Acceptability of Injectable Antiretroviral Therapy in Australian Travelers With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 86, e13-e15.	0.9	0
112	<scp>COVID</scp> â€19: looking backward. Internal Medicine Journal, 2021, 51, 1203-1204.	0.5	0
113	Hepatitis C virus in people with serious mental illness: An analysis of the care cascade at a tertiary health service with a pilot â€~identify and treat' strategy. Internal Medicine Journal, 2021, , .	0.5	0
114	Integrating Hepatitis C Virus Treatment Programs Within Community Mental Health. Psychiatric Services, 2022, 73, 946-949.	1.1	0
115	When pandemics collide: measuring the impact of coronavirus disease 2019 on people with HIV. Aids, 2022, 36, 473-474.	1.0	0
116	Congenital asplenia study: clinical and laboratory characterisation of adults with congenital asplenia. Annals of Hematology, 2022, , 1.	0.8	0
117	Outcomes in Medicareâ€ineligible people living with <scp>human immunodeficiency virus</scp> in a large healthcare network in Melbourne 2004–2019. Internal Medicine Journal, 2022, 52, 868-871.	0.5	0
118	Breaking the fourth wall: Integrating quality into HIV care. Indian Journal of Medical Research, 2021, 154, 765.	0.4	0